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Transfusion in Portugal
Fátima Nascimento, MD
Over the last 30 years transfusion practice has 
undergone significant progress. However, although 
opinion makers have enforced individual govern-
ments as well as the European Union as a whole 
to take measures for improvement of the quality 
and safety of blood and blood components, not so 
much has yet been done regarding the quality and 
safety of their use. 
The inclusion of near miss events in the hae-
movigilance system (HvS) and the extension of 
this system over the clinical stage has facilitated 
the monitoring and improvement of the clinical 
setting of the blood transfusion chain. In Portugal, 
the notification to the HvS is mandatory only for 
the EU requirements and voluntary for all types 
and severity of adverse reactions and events. After 
the implementation of HvS as a national system, 
the errors and near miss events referring to the 
whole transfusion chain (from donor to recipient) 
have also been included. All the notifications to 
the HvS are performed through a website that 
is now complete although it had taken two years 
for the structure to be fully implemented. Online 
notification facilitates prompt transfusion-risk 
assessment at a national level. The major conclusion 
to be drawn from such transfusion-risk assessment 
is that in Portugal misidentification of the patient 
during pre-transfusion sample collection or just 
before transfusion seems to be the main cause of 
adverse events and reactions. If undetected, these 
misidentifications may result in acute hemolytic 
reactions that need to be promptly and correctly 
recognized and treated in order to avoid fatal con-
sequences. 
Although much has already been done in this 
respect there is still room for improvement regard-
ing the clinical part of transfusion chain. The devel-
opment and publication of national “standards for 
clinical guidance” which refer to decision-making 
in transfusion are a starting point for clinical audits 
to be performed in the near future. 
The articles in this issue of the JTM quarterly 
present alternatives to blood components as well 
as strategies to reduce the use of allogeneic blood 
and to correct nutritional deficiencies. The use of 
Erythropoietic Stimulating Agents has been referred 
to. The understanding of the haemostatic system has 
also been subjected to major revision, and therapeu-
tic choices in massive haemorrhage are now being 
shifted to specific plasma derivatives.
The worldwide economic crisis has forced in-
dividual countries to seek measures for reduction 
of blood transfusion costs. Portugal is no exception 
and the process of modification of the structure and 
policies in the transfusion field has already been 
started. To face this economic challenge there is 
an ongoing consolidation of the Blood Transfusion 
System Organisation in Portugal. In order to secure 
self-sufficiency in blood and blood components the 
Blood Centres have become merged with Trans-
plantation Centres and the consolidation process 
is dynamic. Blood Donation Sites have been estab-
lished in hospitals and they are closely linked to 
the Blood Centres. Up to date self-sufficiency in 
plasma derivatives has not yet been achieved but 
we expect to succeed in this respect through the 
call-for-tender procedure. 
Transfusion Medicine Services (TMS), as we 
call the Hospital Blood Banks, are now clearly 
dedicated to support the transfusion practices, 
nevertheless blood transfusion cost represents an 
important quota of hospital budgets. An attempt to 
estimate such costs is also forwarded in this issue 
of the Journal.
In conclusion, it may be said that transfusion 
service in Portugal has undergone satisfactory 
evolution: quality systems have been implemented 
in all Blood Centres and in almost all Transfusion 
Medicine Services; some hospitals of excellence 
introduce new therapies based on blood compo-
nents; virus inactivation technology is applied to 
plasma and platelets/platelet concentrates while 
molecular biology technique is also in place for 
some aspects of immune haematology. Some of 
these subjects will be further presented and dis-
cussed in this Journal. 
